Targeting the RNA regulator HuR in acute traumatic brain injury mitigates secondary injury and improves functional outcome by suppressing neuroinflammation
- 1University of Alabama at Birmingham
Abstract
Traumatic brain injury (TBI) affects ~2.5 million people annually in the US. Minutes after TBI, microglia and astrocytes initiate a neuroinflammatory cascade which promotes secondary injury via cytotoxicity, blood-brain barrier damage, edema, and immune cell recruitment. HuR, an RNA regulator, plays a critical role in the glial response by promoting the expression of proinflammatory mediators including IL-6, IL-1{beta}, TNF-, COX-2, CCL2, and CXCL1 via adenine and uridine-rich elements in the 3' untranslated region of their mRNAs. Here, we assessed SRI-42127, a small molecule HuR inhibitor developed by our group, on neuroinflammatory responses, secondary injury, and functional outcome after TBI. Male mice underwent controlled cortical impact (CCI) followed by peripheral administration of SRI-42127. Functional outcomes assessed included: motor function (balance beam/rotarod) and memory function (object location/recognition). Edema, lesion volume, and BBB permeability were assessed by MRI, brain water content, and Evans blue dye extravasation. HuR nucleocytoplasmic translocation, neuronal loss/apoptosis, microglial and astrocyte activation, and neutrophil infiltration were quantified by immunohistochemistry. Proinflammatory mediator induction was assessed by RT-qPCR and/or immunoblot. Results showed that SRI-42127 treatment improved spatial memory and fine motor performance in the first week in parallel with a reduction in edema, vascular permeability, lesion size, and neuronal loss/apoptosis. There was attenuated microglial activation and astrogliosis, decreased neutrophil infiltration, and suppression of proinflammatory mediator induction. Mechanistically, SRI-42127 inhibited HuR nucleocytoplasmic translocation in microglia and astrocytes. In summary, SRI-42127 potently suppresses neuroinflammation and secondary injury after TBI, improves functional outcomes, and identifies HuR as a new therapeutic target in TBI.
Related
- Dendrimer Delivered shRNA Targeting the CCL20-CCR6 Axis Suppresses Complement-Mediated Microglial Synaptic Pruning and Ameliorates Chronic Neuroinflammation After Repetitive Traumatic Brain Injury
- Cerebral microthrombi promote focal Cav-1-dependent blood-brain barrier impairment, triggering neuroinflammation and neuronal damage after traumatic brain injury
- The cGAS-STING pathway in traumatic brain injury: mechanisms of neuroinflammation and therapeutic strategies
- Sex-Dependent Effects of Creatine Hydrochloride on Neuroinflammation, Neuronal Survival, and Inhibitory Synaptic Remodeling Following Traumatic Brain Injury in Mice.
- A Nominally Safe Dose of Fumonisins Induces Mild Neuroinflammation in Chickens by Targeting Sphingolipids and Oxylipins but Not Cytokines
BibTeX
@misc{king2026targeting,
title = {{Targeting the RNA regulator HuR in acute traumatic brain injury mitigates secondary injury and improves functional outcome by suppressing neuroinflammation}},
author = {P. H. King and M. A. Husain and B. Sheline and R. Smith and O. T. P. Trinh and A. P. Bennett and M. Bolding and S. Keshava and L. B. Nabors and N. Filippova},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.22.761057},
url = {https://www.biorxiv.org/content/10.64898/2026.10.22.761057v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Targeting the RNA regulator HuR in acute traumatic brain injury mitigates secondary injury and improves functional outcome by suppressing neuroinflammation
AU - P. H. King
AU - M. A. Husain
AU - B. Sheline
AU - R. Smith
AU - O. T. P. Trinh
AU - A. P. Bennett
AU - M. Bolding
AU - S. Keshava
AU - L. B. Nabors
AU - N. Filippova
PY - 2026
DA - 2026/10/22
PB - bioRxiv
DO - 10.64898/2026.10.22.761057
UR - https://www.biorxiv.org/content/10.64898/2026.10.22.761057v1
AB - Traumatic brain injury (TBI) affects ~2.5 million people annually in the US. Minutes after TBI, microglia and astrocytes initiate a neuroinflammatory cascade which promotes secondary injury via cytotoxicity, blood-brain barrier damage, edema, and immune cell recruitment. HuR, an RNA regulator, plays a critical role in the glial response by promoting the expression of proinflammatory mediators including IL-6, IL-1{beta}, TNF-, COX-2, CCL2, and CXCL1 via adenine and uridine-rich elements in the 3' untranslated region of their mRNAs. Here, we assessed SRI-42127, a small molecule HuR inhibitor developed by our group, on neuroinflammatory responses, secondary injury, and functional outcome after TBI. Male mice underwent controlled cortical impact (CCI) followed by peripheral administration of SRI-42127. Functional outcomes assessed included: motor function (balance beam/rotarod) and memory function (object location/recognition). Edema, lesion volume, and BBB permeability were assessed by MRI, brain water content, and Evans blue dye extravasation. HuR nucleocytoplasmic translocation, neuronal loss/apoptosis, microglial and astrocyte activation, and neutrophil infiltration were quantified by immunohistochemistry. Proinflammatory mediator induction was assessed by RT-qPCR and/or immunoblot. Results showed that SRI-42127 treatment improved spatial memory and fine motor performance in the first week in parallel with a reduction in edema, vascular permeability, lesion size, and neuronal loss/apoptosis. There was attenuated microglial activation and astrogliosis, decreased neutrophil infiltration, and suppression of proinflammatory mediator induction. Mechanistically, SRI-42127 inhibited HuR nucleocytoplasmic translocation in microglia and astrocytes. In summary, SRI-42127 potently suppresses neuroinflammation and secondary injury after TBI, improves functional outcomes, and identifies HuR as a new therapeutic target in TBI.
ER -